Home|Journals|Articles by Year|Audio Abstracts

Original Article

Majmaah J Heal Sci. 2015; 3(1): 28-32

The high Percentages of Anti-thyroid Antibodies Positive SLE Patients at Sheikh Zayed Hospital, Lahore (Pakistan)

Muqaddas Riaz, Nadeem Afzal, Tafazzul H Mahmud, Faheem Shahzad, Sabrina Rasheed, Aflak Rasheed.


BACKGROUND & OBJECTIVES: Systemic lupus erythmatosus (SLE) is an autoimmune disease and more than 100 auto antibodies have been detected in SLE. The present study was designed to determine the presence of anti-thyroid antibodies (ATA) in SLE patients.

METHODS: It was a descriptive study and 42-SLE patients positive for anti-nuclear antibodies (ANA) and or anti-ds DNA (ds-DNA) antibodies were selected from Department of Rheumatology, Sheikh Zayed Hospital Lahore. Blood sample was collected and ATA was determined by indirect immunofluorescence technique.

RESULTS: Thirty-nine (39) (92.9%) and 32 (76.2%) patients had ANA and ds-DNA antibodies respectively. On comparison, it was not statistically significant. Twenty- three (23) (54.76%) subjects had ATA and on comparison, it was not statistically significant. All the positive patients for ATA were females.

CONCLUSION: Sensitivity of ANA and ds-DNA positive suspected SLE subjects to have ATA in their serum was 74%. About 55% of SLE patients were positive for ATA.

Key words: Systemic lupus erythematosus, Anti-thyroid antibodies, Immunofluorescence

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.